Nu.Q® Discover epigenetic profiling for target identification to validation in clinical studies

Nu.Q® Discover White Paper: The epigenetic keys to unlocking the full potential of immunotherapy

February 13, 2024

Our new White Paper is a deep dive into the science of epigenetics, and its potential to reveal deep insights into how our bodies react and respond to medication during cancer therapy and immunotherapies.

With the rise of novel immunotherapies, there is a need for markers that are able to predict treatment response or ineffectiveness, in order to improve patient outcomes.

Read the full White Paper here.